


JUL 14 1999

K991343



IRVINE SCIENTIFIC

**510(k) SUMMARY AS REQUIRED BY SECTION 807.92(c)**

**Submitted by:**

Irvine Scientific Sales Co., Inc.  
2511 Daimler Street  
Santa Ana, CA 92705-5588

Telephone: (800) 437-5706  
Facsimile: (949) 261-6522

Contact: Roberta L. Johnson

Date Submitted: April 16, 1999

**Device Identification:**

Trade Name: PVP-Polyvinylpyrrolidone  
Common Name: Sperm Immobilization Medium  
Classification Name: Reproductive Media (21 CFR, 886.6180)

**Predicate Device:**

Notice of Final Rule, 63 FR 48428, Docket number 97N-0335

**Description:**

PVP consists of polyvinylpyrrolidone that has been dissolved in ultra-pure water and lyophilized.

**Intended Use:**

PVP is intended for use as an aid in the immobilization and isolation of sperm prior to intracytoplasmic sperm injection (ICSI) procedures.

**Technological Characteristics:**

Intracytoplasmic sperm injection (ICSI) procedures are typically performed in those instances where infertility is either caused by severe male factor (i.e. poor quality or insufficient number of sperm) or is of unknown cause, and where traditional in vitro fertilization procedures have not resulted in pregnancy. In ICSI, viable sperm cells are concentrated and purified, and then isolated in a culture dish, where a single cell is aspirated into a pipette or syringe, and injected into an ovum. PVP is used to assist in the isolation and immobilization of sperm, prior to ICSI procedures.

**Performance Data:**

PVP has been used in a variety of clinical settings, for its intended use, for a number of years. In that time, the product has become one of standard media used for the immobilization and isolation of human sperm cells for use in ICSI procedures.

**Additional Information:**

Endotoxin, hamster sperm penetration assay performance and sterility tests will be performed as a condition of release for this product. Results of all release assays performed will be reported on a lot-specific certificate of analysis, and will be indicated on the labeling.

**Conclusion:**

The conclusion from a review of the historical information contained in professional literature shows that PVP is suitable for its intended use, and meets the criteria outlined in the Notice of Final Rule, 63 FR 48428, Docket number 97N-0335.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUL 14 1999

Ms. Roberta L. Johnson  
Manager, Regulatory Affairs  
Irvine Scientific, Inc.  
2511 Daimler Street  
Santa Ana, CA 92705-5588

Re: K991343  
Polyvinylpyrrolidone (PVP)  
Dated: April 16, 1999  
Received: April 19, 1999  
Regulatory Class: II  
21 CFR §884.6180/Procode: 85 MQL

Dear Ms. Johnson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

CAPT Daniel G. Schultz, M.D.  
Acting Director, Division of Reproductive,  
Abdominal, Ear, Nose and Throat,  
and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**INDICATIONS FOR USE STATEMENT (page 1 of 1)**

510(K) Number: K991343

Device Name: PVP (Polyvinylpyrrolidone)

Indications for Use:

PVP (polyvinylpyrrolidone) is intended for use in assisted reproductive technology procedures involving the manipulation of gametes. Specifically, PVP is intended for use as a medium for the immobilization of sperm during intracytoplasmic sperm injection (ICSI) procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

R. A. Phelps  
(Division Sign-Off)  
Division of Reproductive, Abdominal, ENT,  
and Radiological Devices  
510(k) Number K991343

Prescription Use   
(Per 21 CFR 801.109)